This is in contrast to the more heterogeneous group of aggressive B‐cell lymphomas with MYC and BCL6 rearrangements that are recognized as a provisional entity in the ICC, while they fall into the DLBCL, NOS, or the HGBL, NOS, groups in the WHO-HAEM5. The gene discussed is MYC; the disease is intrahepatic cholangiocarcinoma.